Open AccessFollow‐up Study of Patients Treated with Monoclonal Antibody‐Drug Conjugate: Report of 77 Cases with Colorectal Cancer
Author(s) -
Takahashi Toshio,
Yamaguchi Toshiharu,
Kitamura Kazuya,
Noguchi Akinori,
Honda Mitsuyo,
Otsuji Eigo
Publication year - 1993
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1993.tb00188.x
Subject(s) - medicine , colorectal cancer , neocarzinostatin , metastasis , gastroenterology , monoclonal antibody , chemotherapy , cancer , antibody , drug , survival rate , surgery , oncology , pharmacology , immunology , dna , biology , genetics
A total of 77 patients with advanced colorectal cancer, including postoperative patients with liver, lung and peritoneal metastases, were treated with single or multiple injections of monoclonal antibody A7‐neocarzinostatin (A7‐NCS). A follow‐up study of the patients treated with A7‐NCS was done and the clinical outcome was compared with that of patients given other chemotherapies. In the postoperative patients with liver metastasis, the A7‐NCS treatment prolonged survival time when compared with systemic administration of anticancer drugs, while it showed a similar survival time to chemoembolization using multiple anticancer agents suspended in a lipid contrast medium. Among the patients who underwent surgical resection of primary cancer, with or without liver metastasis, there was no difference in overall 5‐year survival rate between the group treated with A7‐NCS and the group treated with the other chemotherapies. However, the survival time of the patients treated with A7‐NCS was longer than that of the patients treated with the other chemotherapies. In addition, the patients given a higher dose of A7‐NCS had a longer survival time than the patients given a lower dose of A7‐NCS. Human anti‐mouse antibody was detected in all the A7‐NCS‐treated patients examined. There were no serious side effects in any of the patients given A7‐NCS. Thus, this study indicates that the A7‐NCS treatment is safe and useful for colorectal cancer patients, though some problems remain, such as optimization of injection dose, route, interval, etc., and overcoming human anti‐mouse antibody development.